Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we engineered T cells with a CAR consisting of the extracellular domain of heregulin-1β (HRG1β) that is a natural ligand for HER3/HER4, and evaluated the specific cytotoxicity of these CAR-T cells in cultured HER3 positive breast cancer cells and xenograft tumors.
|
29127433 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented success among hematologic tumors, but its role in treating solid tumors is still unclear.
|
30886654 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While immunotherapy with chimeric antigen receptor T (CAR-T) cells has shown much promise in haematological malignancies, their efficacy for solid tumours is challenged by the lack of tumour-specific antigens required to avoid on-target, off-tumour effects.
|
30121627 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In in vivo experiment, we confirmed how DOC enhanced the recruitment of HER2-CAR T cells to tumor sites.
|
30744691 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review we discuss some of the mechanistic contributions intrinsic to the CAR-T construct, the tumor being treated, and the individual patient that impact the development and severity of CRS and neurotoxicity.
|
31355491 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because CAR-T cells recognize tumor cells independent of their expression of human leukocyte antigen (HLA) molecules, tumors that escape conventional T cells by downregulating HLA and/or mutating components of the antigen processing machinery can be eliminated.
|
25621840 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This dependence on CAR potentially limits the use of adenovirus in gene therapy, since CAR is expressed in many tissues of the body, and expression of CAR may be low or lost upon progression of certain tumors.
|
15389777 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface antigens by transferring chimeric antigen receptor (CAR) genes is becoming an effective strategy to combat cancer.
|
31004624 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These responses are strictly limited and are tightly linked, since β-catenin is activated in nearly all of the CAR-dependent tumours generated by the tumour promoter phenobarbital.
|
25661872 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Site-directed, magnetically-targeted delivery of the HmT-PCION elicited significantly greater therapeutic efficacy versus treatment with naked HmT or HmT-PCION without MGF in CAR-negative MCF7 tumors.
|
26164117 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, male transgenic mice expressing human CAR and PXR were used to detect possible differences between wild-type (WT) and humanized mice in their response to CAR activation in a tumor initiation/promotion experiment with a single injection of the tumor initiator N-nitrosodiethylamine preceding chronic PB treatment for 10 months.
|
24863967 |
2014 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
T-cell mediated immune responses specific for peptides from the murine scFv antigen-binding domain of the CAR can develop in patients and result in premature elimination of CAR T-cells increasing the risk of tumor relapse.
|
28202953 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection.
|
30649750 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient to eliminate the targeted tumor.
|
29245005 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, CD19-GITR-CD3 CAR-T cells had significant cytotoxic activity against CD19-positive cancer cells <i>in vitro</i> and in Raji xenograft tumors <i>in vivo</i>.
|
29772559 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IP delivery of CAR-T cells has shown demonstrable suppression of tumors expressing carcinoembryonic antigen.
|
30103457 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Intratumoral injection of the Ad.Lp-CD-IRES-E1A(MRGD) vector following the intraperitoneal injection of 5FC into xenotransplanted human breast cancer cell lines which have low expression level of CAR led to greater degree of tumor regression in vivo than did the intratumoral injection of control adenoviral vectors not so modified.
|
16179927 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells lacking all three NR4A transcription factors (Nr4a triple knockout) promoted tumour regression and prolonged the survival of tumour-bearing mice.
|
30814732 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mean value of CAR expression was significantly lower in 22 Grade IV tumors as compared to the values for 6 Grade II (p = 0.01) and 6 Grade III (p = 0.01) tumors.
|
12516090 |
2003 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with GSK3-inhibited CAR-T cells resulted in 100% tumor elimination during the tumor-rechallenge experiment in GBM-bearing animals and increased accumulation of memory CAR-T cells in secondary lymphoid organs.
|
29959057 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have demonstrated that aberrantly glycosylated cell surface proteins on tumor cells are amenable CAR targets.
|
30510550 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By comparison, the CD4+ CAR T cells persisted after tumor challenge and sustained their effector potency.
|
29769444 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, scFV-3H11 CAR-T cells are able to kill tumor cells accompanied with increased interleukin-2 and interferon-γ secretion <i>in vitro</i>, and reduced the tumor burden in GC cell lines and patient-derived GC cells <i>in vivo</i>.
|
29849787 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicated that the disruption of PD-1 enhanced the <i>in vivo</i> anti-tumor activity of CAR T cells against HCC, improved the persistence and infiltration of CAR T cells in the NSG mice bearing the tumor, and strengthened the inhibition of tumor-related genes expression in the xenograft tumors caused by the GPC3-CAR T cells.
|
30327605 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of AxdAdB3-F/RGD into CAR-negative prostate cancer cell xenografts in nude mice inhibited tumor growth.
|
26799485 |
2016 |